BMJ Open (May 2024)

Do patients with nephrotic syndrome have an increased risk of osteoporosis? A nationwide population-based retrospective cohort study in Taiwan

  • Chi-Hsiang Chung,
  • Chang-Huei Tsao,
  • Wu-Chien Chien,
  • Chia-Chao Wu,
  • Fu-Huang Lin,
  • Chen-Yi Liao,
  • Kuang-Yu Wei,
  • Min-Feng Tseng,
  • Pauling Chu

DOI
https://doi.org/10.1136/bmjopen-2023-080858
Journal volume & issue
Vol. 14, no. 5

Abstract

Read online

Objectives To evaluate whether nephrotic syndrome (NS) and further corticosteroid (CS) use increase the risk of osteoporosis in Asian population during the period January 2000–December 2010.Design Nationwide population-based retrospective cohort study.Setting All healthcare facilities in Taiwan.Participants A total of 28 772 individuals were enrolled.Interventions 26 614 individuals with newly diagnosed NS between 2000 and 2010 were identified and included in out study. 26 614 individuals with no NS diagnosis prior to the index date were age matched as controls. Diagnosis of osteoporosis prior to the diagnosis of NS or the same index date was identified, age, sex and NS-associated comorbidities were adjusted.Primary outcome measure To identify risk differences in developing osteoporosis among patients with a medical history of NS.Results After adjusting for covariates, osteoporosis risk was found to be 3.279 times greater in the NS cohort than in the non-NS cohort, when measured over 11 years after NS diagnosis. Stratification revealed that age older than 18 years, congestive heart failure, hyperlipidaemia, chronic kidney disease, liver cirrhosis and NS-related disease including diabetes mellitus, hepatitis B infection, hepatitis C infection, lymphoma and hypothyroidism, increased the risk of osteoporosis in the NS cohort, compared with the non-NS cohort. Additionally, osteoporosis risk was significantly higher in NS patients with CS use (adjusted HR (aHR)=3.397). The risk of osteoporosis in NS patients was positively associated with risk of hip and vertebral fracture (aHR=2.130 and 2.268, respectively). A significant association exists between NS and subsequent risk for osteoporosis.Conclusion NS patients, particularly those treated with CS, should be evaluated for subsequent risk of osteoporosis.